|
The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study. |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb |
Speakers' Bureau - Bristol-Myers Squibb; GlaxoSmithKline |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune |
|
|
Consulting or Advisory Role - BMS; Ipsen; MSD; Novartis; Pfizer |
Speakers' Bureau - BMS; Ipsen; MSD; Novartis; Pfizer |
Research Funding - Novartis (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; MSD Italy |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Janssen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Roche |
Speakers' Bureau - AstraZeneca; Eisai |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen Oncology; Pfizer |
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Medivation; Janssen; MSD Oncology |
Speakers' Bureau - Astellas Pharma |
|
|
Consulting or Advisory Role - Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol Myers Squibb Foundation; Ipsen; Janssen; MSD; Novartis; Pfizer; Sanofi |
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Ipsen; Janssen; MSD; Novartis; Pfizer; Sanofi |
|